The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex - 16/07/18
Abstract |
Background |
The immune response to melanoma is manifested locally by tumor-infiltrating lymphocytes (TILs). Men and women are known to have varying patterns of immunity, yet sex-specific prognostic implications of TILs have not been explored.
Methods |
Patients who had clinically localized primary melanoma with a Breslow thickness of 0.76 mm or more and underwent sentinel lymph node (SLN) biopsy at our institution were identified. The association between TILs (absent, nonbrisk, and brisk) and SLN positivity was evaluated by using logistic regression. Overall survival (OS) was evaluated by TIL status and sex.
Results |
Among 1367 patients identified, 794 were men. TILs were brisk in 143 lesions, nonbrisk in 903, and absent in 321, which did not vary by sex (P = .71). SLN positivity was associated with TILs among men (brisk, 3.8%; nonbrisk, 16.9%; and absent, 26.6% [P < .001]). In contrast, there was no association between SLN positivity and TILs among women (P = .49). Interaction between brisk TILs and sex on SLN positivity was significant (P = .029). Among men, presence of brisk TILs was associated with prolonged OS (P = .038) but not after adjustment for SLN status (P = .42). There was no association between TIL status and OS among women.
Limitations |
Findings from this single-institution study have yet to be validated by other research groups.
Conclusions |
The implications of TILs in predicting SLN positivity appear to be more relevant for men than for women.
Le texte complet de cet article est disponible en PDF.Key Words : immune response, melanoma, prognosis, sentinel lymph node, sex, tumor-infiltrating lymphocytes
Abbreviations used : DFS, HR, OR, OS, SLN, SLNB, TILs
Plan
Funding sources: Dr Gimotty received support from the Specialized Programs of Research Excellence on Skin Cancer (grant P50-CA174523). |
|
Conflicts of interest: None disclosed. |
|
Reprints not available from the authors. |
Vol 79 - N° 2
P. 245-251 - août 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?